about
3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 A resolution: kinetic and molecular dynamic correlatesNovel huprine derivatives with inhibitory activity toward β-amyloid aggregation and formation as disease-modifying anti-Alzheimer drug candidates.Huprines as a new family of dual acting trypanocidal-antiplasmodial agentsExpanding the multipotent profile of huprine-tacrine heterodimers as disease-modifying anti-Alzheimer agents.Cholinergic drugs in pharmacotherapy of Alzheimer's disease.Undifferentiated and differentiated PC12 cells protected by huprines against injury induced by hydrogen peroxideDimeric and hybrid anti-Alzheimer drug candidates.Huprines for Alzheimer's disease drug development.Exploring the size limit of templates for inhibitors of the M2 ion channel of influenza A virus.Synthesis and pharmacological evaluation of (2-oxaadamant-1-yl)amines.Role of the viral hemagglutinin in the anti-influenza virus activity of newly synthesized polycyclic amine compounds.Potentiation effects of (+/-)huprine X, a new acetylcholinesterase inhibitor, on nicotinic receptors in rat cortical synaptosomes.Polycyclic N-benzamido imides with potent activity against vaccinia virus.Effect of huprine X on β-amyloid, synaptophysin and α7 neuronal nicotinic acetylcholine receptors in the brain of 3xTg-AD and APPswe transgenic mice.Tacrine-based dual binding site acetylcholinesterase inhibitors as potential disease-modifying anti-Alzheimer drug candidates.The pharmacology of novel acetylcholinesterase inhibitors, (+/-)-huprines Y and X, on the Torpedo electric organ.Synthesis, in vitro pharmacology, and molecular modeling of syn-huprines as acetylcholinesterase inhibitors.Huprine X and huperzine A improve cognition and regulate some neurochemical processes related with Alzheimer's disease in triple transgenic mice (3xTg-AD).Neuroprotective effects of (+/-)-huprine Y on in vitro and in vivo models of excitoxicity damage.Alternative syntheses of the new D2d symmetric tetramethyl tricyclo- [3.3.0.0(3,7)]octane-1,3,5,7-tetracarboxylate.(+/-)-huprine Y, (-)-huperzine A and tacrine do not show neuroprotective properties in an apoptotic model of neuronal cytoskeletal alteration.Generation and reactions of two new functionalized tricyclo[3.3.0.0 3,7]oct-1(5)-ene derivatives.Evaluation of cryptolepine and huperzine derivatives as lead compounds towards new agents for the treatment of human African trypanosomiasis.Synthesis and pharmacological evaluation of several ring-contracted amantadine analogs.Effects of (+/-)-huprine Y and (+/-)-huprine Z, two new anticholinesterasic drugs, on muscarinic receptors.Synthesis and absolute configuration of novel N,O-psiconucleosides using (R)-N-phenylpantolactam as a resolution agent.Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.Cholesterol-diaryl ketone stereoisomeric dyads as models for "clean" type I and type II photooxygenation mechanisms.Nicotinic-receptor potentiator drugs, huprine X and galantamine, increase ACh release by blocking AChE activity but not acting on nicotinic receptors.Behavioural effects and regulation of PKCalpha and MAPK by huprine X in middle aged mice.Characterisation of the anticholinesterase activity of two new tacrine-huperzine A hybrids.Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.Huprine-tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer's and prion diseases.Dehalogenation of 1,3-diiodotricyclo[3.3.0.0(3,7)]octane: generation of 1,3-dehydrotricyclo[3.3.0.0(3,7)]octane, a 2,5-methano-bridged [2.2.1]propellane.Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treatment of Alzheimer's disease.Alternative Access to Functionalized 2,8-Ethanonoradamantane Derivatives.Synthesis and evaluation of tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease.Acetylcholinesterase triggers the aggregation of PrP 106-126Effect of acetylcholinesterase inhibitors on AChE-induced PrP106-126 aggregationEfficient and Selective Photogeneration of Cholesterol-Derived Radicals by Intramolecular Hydrogen Abstraction in Model Dyads
P50
Q27638038-43447712-C152-463E-BCC9-1445D2B5843FQ33699095-4979CC64-0BB6-493D-B365-693FD09DEB37Q33818962-AFB8DE78-FCAA-466D-94CB-B83EFDE12E20Q34124395-1658C876-2159-48AC-B697-7D9AFD734BA3Q34153475-281EB3C8-9823-4190-A8FD-9C964CA3664CQ35004992-4E2278A6-8DFB-4E4D-B799-C55ADB14EA4CQ36395551-0C38BF3E-29FE-40B8-9589-1290A42AB842Q38088283-0600B6E5-6A30-4E69-91E1-0E665406090FQ38452544-FE9B4307-F0A1-4C3A-9857-28B172C4B989Q39140111-B4A20D3A-B8BB-41E6-8B0D-DB2728222724Q42288142-00109D8E-6BA9-4267-B566-9777CD3C295DQ42453700-4D9AB524-E405-4649-B4E4-B7C1B2A8A3ACQ42850381-E2225AC3-EC8D-45E3-9F74-89A862BDF0A6Q42944835-582B27B2-3DBB-4313-B666-0A19FD2375E1Q43157584-8CDF509A-DDD9-47C0-8C13-757DBD88E864Q43634918-33225C00-9A4D-430D-B1C4-B6D3C4180DC0Q43821288-48F834E3-6B8E-428E-B489-BC00CA8B8D4EQ44285130-FC15D9B5-D171-4948-AF2E-DA1221B88BA3Q44395839-60C5B30C-7C68-4D88-A4B1-91D3BE9294A3Q44629830-DBDC3FD5-5196-435A-86B1-B94781CED929Q45234660-B2D66E54-6010-443E-9FDA-981DF2E7F0E7Q45282151-2D19C01C-6DDA-4B99-A360-F161C998A92FQ46049134-6785956B-8112-4C63-8BDE-F0C47C5E2E6BQ46292312-B655A330-4514-4203-B82A-958DB27DB879Q46432286-C3805D2C-AF25-48F7-989B-7548DF2F870BQ46459280-79E423FE-8729-49DD-8E12-7430EA8D1029Q46563660-902E70EF-BACD-4B26-94F0-4D2CFE88057FQ46739495-DB6F5B69-A104-4D8E-9E0D-B81FBB7979E8Q46774214-0B260DCD-4167-4B14-B8FB-88BDC25FA9BCQ48249717-78295171-37EB-4CED-93DF-58A31DBDEFA4Q48332165-8E55E766-E921-40AC-870C-3B11392F5EAAQ48491553-7523F25A-1827-4C53-8A6E-EEF3E44179B4Q48765567-6146E4B1-CB3D-49A8-9E19-E7A8744B80E9Q51929292-DD5BDDC9-E3A7-4C67-B3B3-F531577B473BQ53232714-A310438D-7CF5-4A03-8AD1-546B88E507B6Q53256030-18D2379D-1535-41A2-9542-2F908D491AB1Q53330026-C4A455DF-A920-459C-AAEE-9A128CC6BEBEQ57217215-550AA8F8-168D-42E2-8D14-9D47E07427ECQ57217497-339505B6-658D-4D41-806D-759FFDD2405BQ57976781-F9168F9C-5C39-4DF4-989B-CA0674ECB496
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Pelayo Camps
@ast
Pelayo Camps
@en
Pelayo Camps
@es
Pelayo Camps
@nl
Pelayo Camps
@sl
type
label
Pelayo Camps
@ast
Pelayo Camps
@en
Pelayo Camps
@es
Pelayo Camps
@nl
Pelayo Camps
@sl
altLabel
P Camps
@en
Pelayo Camps García
@en
prefLabel
Pelayo Camps
@ast
Pelayo Camps
@en
Pelayo Camps
@es
Pelayo Camps
@nl
Pelayo Camps
@sl
P108
P214
P244
P1053
D-4421-2014
P106
P1153
7006417899
P1580
P21
P214
P244
ns2018003081
P31
P3829
P496
0000-0002-9633-3525
P569
2000-01-01T00:00:00Z
P735
P7859
lccn-ns2018003081